Drugs / PvCS N+C+R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04739917 | Jun 2021 → Jun 2022 | Plasmodium vivax malaria | Malaria Vaccine and Drug Development Center | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PvCS N+C+R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04739917 ↗ |
| Modality | Vaccine | “Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers” NCT04739917 ↗ |